

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



PRODUCT INFORMATION



CYR-101

Item No. 29773

CAS Registry No.: 359625-79-9

Formal Name: 2-[[1-[2-(4-fluorophenyl)-

> 2-oxoethyl]-4-piperidinyl] methyl]-2,3-dihydro-1H-

isoindol-1-one


MF: $C_{22}H_{23}FN_2O_2$

FW: 366.4 **Purity:**

UV/Vis.: λ_{max} : 229, 244 nm

A solid Supplied as: -20°C Storage: Stability: ≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

CYR-101 is supplied as a solid. A stock solution may be made by dissolving the CYR-101 in the solvent of choice, which should be purged with an inert gas. CYR-101 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of CYR-101 in these solvents is approximately 3, 5, and 10 mg/ml, respectively.

CYR-101 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, CYR-101 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. CYR-101 has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

CYR-101 is a dual antagonist of the serotonin (5-HT) receptor subtype 5-HT_{2 Δ} and sigma-2 (σ_2) receptors $(K_i s = 7.53 \text{ and } 8.19 \text{ nM}, \text{ respectively}).^1$

Reference

1. Davidson, M., Saoud, J., Staner, C., et al. Efficacy and safety of MIN-101: A 12-week randomized, double-blind, placebo-controlled trial of a new drug in development for the treatment of negative symptoms in schizophrenia. Am. J. Psychiatry 174(12), 1195-1202 (2017).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/27/2020

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM